Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3

verfasst von: Heying Chu, Xudong Chen, Huaqi Wang, Yuwen Du, Yuanyuan Wang, Wenqiao Zang, Ping Li, Juan Li, Jingxia Chang, Guoqiang Zhao, Guojun Zhang

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Our previous studies have showed that metastasis-associated protein 3 (MTA 3) is overexpressed in non-small cell lung cancer (NSCLC) tissue, and increased MTA3 mRNA levels is a risk factor of lymph node metastasis. Using bioinformatics analyses, we found that MTA3 was a potential target of miR-495. However, the pathophysiological role of miR-495 and its relevance to the growth and development of NSCLC have yet to be investigated. The purpose of this study was to elucidate the molecular mechanisms by which miR-495 acts as a tumor suppressor in NSCLC. qRT-PCR data showed significant downregulation of miR-495 in 56 NSCLC tissue samples and 5 lung cancer cell lines, compared with their adjacent normal tissue; furthermore, western blotting analysis revealed MTA3 protein was overexpressed in the tumor samples compared with the matched adjacent normal tissue. MiR-495 was shown to not only inhibit the proliferation of lung cancer cells (A549 and Calu-3) but also to inhibit cell migration in vitro. Using western blotting and luciferase assays, MTA3 was identified as a target of miR-495. These findings suggest the importance of miR-495 targeting of MTA3 in the regulation of lung cancer growth and migration.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin. 2010;60(5):277–300.PubMedCrossRef Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin. 2010;60(5):277–300.PubMedCrossRef
2.
3.
Zurück zum Zitat Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122(3):1037–57.PubMedCrossRef Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122(3):1037–57.PubMedCrossRef
4.
Zurück zum Zitat Humphrey GW, Wang Y, Russanova VR, Hirai T, Qin J, Nakatani Y, et al. Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J Biol Chem. 2001;276(9):6817–24.PubMedCrossRef Humphrey GW, Wang Y, Russanova VR, Hirai T, Qin J, Nakatani Y, et al. Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J Biol Chem. 2001;276(9):6817–24.PubMedCrossRef
5.
Zurück zum Zitat Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell. 2003;113(2):207–19.PubMedCrossRef Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell. 2003;113(2):207–19.PubMedCrossRef
6.
Zurück zum Zitat Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis. 2009;26(3):215–27.PubMedCrossRef Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis. 2009;26(3):215–27.PubMedCrossRef
7.
Zurück zum Zitat Bowen NJ, Fujita N, Kajita M, Wade PA. Mi-2/NuRD: multiple complexes for many purposes. Biochim Biophys Acta. 2004;1677(1–3):52–7.PubMedCrossRef Bowen NJ, Fujita N, Kajita M, Wade PA. Mi-2/NuRD: multiple complexes for many purposes. Biochim Biophys Acta. 2004;1677(1–3):52–7.PubMedCrossRef
8.
Zurück zum Zitat Li H, Sun L, Xu Y, Li Z, Luo W, Tang Z, et al. Overexpression of MTA3 correlates with tumor progression in non-small cell lung cancer. Plos One. 2013;8(6):1–8. Li H, Sun L, Xu Y, Li Z, Luo W, Tang Z, et al. Overexpression of MTA3 correlates with tumor progression in non-small cell lung cancer. Plos One. 2013;8(6):1–8.
9.
Zurück zum Zitat Brüning A, Makovitzky J, Gingelmaier A, Friese K, Mylonas I. The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells. Histochem Cell Biol. 2009;132(1):33–8.PubMedCrossRef Brüning A, Makovitzky J, Gingelmaier A, Friese K, Mylonas I. The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells. Histochem Cell Biol. 2009;132(1):33–8.PubMedCrossRef
10.
Zurück zum Zitat Bruning A, Juckstock J, Blankenstein T, Makovitzky J, Kunze S, Mylonas I. The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas. Histol Histopathol. 2010;25(11):1447–56.PubMed Bruning A, Juckstock J, Blankenstein T, Makovitzky J, Kunze S, Mylonas I. The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas. Histol Histopathol. 2010;25(11):1447–56.PubMed
11.
Zurück zum Zitat Zhang H, Stephens LC, Kumar R. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res. 2006;12(5):1479–86.PubMedCrossRef Zhang H, Stephens LC, Kumar R. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res. 2006;12(5):1479–86.PubMedCrossRef
12.
Zurück zum Zitat Dannenmann C, Shabani N, Friese K, Jeschke U, Mylonas I, Bruning A. The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biol Ther. 2008;7(9):1460–7.PubMedCrossRef Dannenmann C, Shabani N, Friese K, Jeschke U, Mylonas I, Bruning A. The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biol Ther. 2008;7(9):1460–7.PubMedCrossRef
13.
Zurück zum Zitat Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res. 2004;64(3):825–9.PubMedCrossRef Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res. 2004;64(3):825–9.PubMedCrossRef
14.
Zurück zum Zitat Iguchi H, Imura G, Toh Y, Ogata Y. Expression of MTA1, a metastasis-associated gene with histone deacetylase activity in pancreatic cancer. Int J Oncol. 2000;16(6):1211–4.PubMed Iguchi H, Imura G, Toh Y, Ogata Y. Expression of MTA1, a metastasis-associated gene with histone deacetylase activity in pancreatic cancer. Int J Oncol. 2000;16(6):1211–4.PubMed
15.
Zurück zum Zitat Jang KS, Paik SS, Chung H, Oh YH, Kong G. MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci. 2006;97(5):374–9.PubMedCrossRef Jang KS, Paik SS, Chung H, Oh YH, Kong G. MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci. 2006;97(5):374–9.PubMedCrossRef
16.
Zurück zum Zitat Xia Y, Chen Q, Zhong Z, Caihua X, Chen W, Liu B, et al. Down-regulation of MiR-30c promotes the invasion of non-small cell lung cancer by targeting MTA1. CELL Physiol Biochem. 2013;32(2):476–85.PubMedCrossRef Xia Y, Chen Q, Zhong Z, Caihua X, Chen W, Liu B, et al. Down-regulation of MiR-30c promotes the invasion of non-small cell lung cancer by targeting MTA1. CELL Physiol Biochem. 2013;32(2):476–85.PubMedCrossRef
17.
Zurück zum Zitat Zheng S, Du Y, Chu H, Chen X, Li P, Wang Y, et al. Analysis of MAT3 gene expression in NSCLC. Diagn Pathol. 2013;8:166 Zheng S, Du Y, Chu H, Chen X, Li P, Wang Y, et al. Analysis of MAT3 gene expression in NSCLC. Diagn Pathol. 2013;8:166
19.
Zurück zum Zitat Wan HY, Guo LM, Liu T, Liu M, Li X, Tang H. Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer. 2010;9(16):1–10. Wan HY, Guo LM, Liu T, Liu M, Li X, Tang H. Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer. 2010;9(16):1–10.
20.
Zurück zum Zitat Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science. 2005;309(5740):1519–24.PubMedCrossRef Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science. 2005;309(5740):1519–24.PubMedCrossRef
21.
Zurück zum Zitat Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet.2006;15(Spec No 1):R17–29 Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet.2006;15(Spec No 1):R17–29
22.
Zurück zum Zitat Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem. 1992;61:441–70.PubMedCrossRef Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem. 1992;61:441–70.PubMedCrossRef
24.
Zurück zum Zitat Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, et al. Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res. 2005;65(20):9287–93.PubMedCrossRef Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, et al. Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res. 2005;65(20):9287–93.PubMedCrossRef
25.
Zurück zum Zitat Ouyang W, Li J, Ma Q, Huang C. Essential roles of PI-3K/Akt/IKKbeta/ NFkappaB pathway in cyclinD1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis. 2006;27(4):864–73.PubMedCrossRef Ouyang W, Li J, Ma Q, Huang C. Essential roles of PI-3K/Akt/IKKbeta/ NFkappaB pathway in cyclinD1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis. 2006;27(4):864–73.PubMedCrossRef
26.
Zurück zum Zitat Zhang H, Singh RR, Talukder AH, Kumar R. Metastatic tumor antigen 3 is a direct corepressor of the Wnt4 pathway. Genes Dev. 2006;20(21):2943–8.PubMedCentralPubMedCrossRef Zhang H, Singh RR, Talukder AH, Kumar R. Metastatic tumor antigen 3 is a direct corepressor of the Wnt4 pathway. Genes Dev. 2006;20(21):2943–8.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Mishra SK, Talukder AH, Gururaj AE, Yang Z, Singh RR, Mahoney MG, et al. Upstream determinants of estrogen receptor-alpha regulation of metastatic tumor antigen 3 pathway. J Biol Chem. 2004;279(31):32709–15.PubMedCentralPubMedCrossRef Mishra SK, Talukder AH, Gururaj AE, Yang Z, Singh RR, Mahoney MG, et al. Upstream determinants of estrogen receptor-alpha regulation of metastatic tumor antigen 3 pathway. J Biol Chem. 2004;279(31):32709–15.PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Fujita N, Kajita M, Taysavang P, Wade PA. Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells. Mol Endocrinol. 2004;18(12):2937–49.PubMedCrossRef Fujita N, Kajita M, Taysavang P, Wade PA. Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells. Mol Endocrinol. 2004;18(12):2937–49.PubMedCrossRef
29.
Zurück zum Zitat Chen Y, Miyazaki J, Nishizawa H, Kurahashi H, Leach R, Wang K. MTA3 regulates CGB5 and Snail genes in trophoblast. Biochem Biophys Res Commun. 2013;433(4):379–84.PubMedCrossRef Chen Y, Miyazaki J, Nishizawa H, Kurahashi H, Leach R, Wang K. MTA3 regulates CGB5 and Snail genes in trophoblast. Biochem Biophys Res Commun. 2013;433(4):379–84.PubMedCrossRef
30.
Zurück zum Zitat Bagheri-Yarmand R, Talukder AH, Wang RA, Vadlamudi RK, Kumar R. Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development. 2004;131(14):3469–79.PubMedCrossRef Bagheri-Yarmand R, Talukder AH, Wang RA, Vadlamudi RK, Kumar R. Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development. 2004;131(14):3469–79.PubMedCrossRef
31.
Zurück zum Zitat Manavathi B, Singh K, Kumar R. MTA family of coregulators in nuclear receptor biology and pathology. Nucl Recept Signal. 2007;5:e010.PubMedCentralPubMed Manavathi B, Singh K, Kumar R. MTA family of coregulators in nuclear receptor biology and pathology. Nucl Recept Signal. 2007;5:e010.PubMedCentralPubMed
32.
Zurück zum Zitat Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994;369(6482):669–71.PubMedCrossRef Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994;369(6482):669–71.PubMedCrossRef
33.
Zurück zum Zitat Resnitzky D, Reed SI. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol. 1995;15(7):3463–9.PubMedCentralPubMed Resnitzky D, Reed SI. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol. 1995;15(7):3463–9.PubMedCentralPubMed
34.
Zurück zum Zitat Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature. 1999;401(6750):297–300.PubMedCrossRef Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature. 1999;401(6750):297–300.PubMedCrossRef
35.
Zurück zum Zitat Hubalek MM, Widschwendter A, Erdel M, Gschwendtner A, Fiegl HM, Muller HM, et al. Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene. 2004;23(23):4187–92.PubMedCrossRef Hubalek MM, Widschwendter A, Erdel M, Gschwendtner A, Fiegl HM, Muller HM, et al. Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene. 2004;23(23):4187–92.PubMedCrossRef
36.
Zurück zum Zitat Noren Hooten N, Abdelmohsen K, Gorospe M, Ejiogu N, Zonderman AB, Evans MK. microRNA expression patterns reveal differential expression of target genes with age. PloS One. 2010;5(5):e10724 Noren Hooten N, Abdelmohsen K, Gorospe M, Ejiogu N, Zonderman AB, Evans MK. microRNA expression patterns reveal differential expression of target genes with age. PloS One. 2010;5(5):e10724
37.
Zurück zum Zitat Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO, Yasuda J. MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PloS One. 2009;4(8):e6677.PubMedCentralPubMedCrossRef Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO, Yasuda J. MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PloS One. 2009;4(8):e6677.PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Qin W, Ren Q, Liu T, Huang Y, Wang J. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett. 2013;587(9):1434–9.PubMedCrossRef Qin W, Ren Q, Liu T, Huang Y, Wang J. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett. 2013;587(9):1434–9.PubMedCrossRef
39.
Zurück zum Zitat Miao LJ, Huang SF, Sun ZT, Gao ZY, Zhang RX, Liu Y, et al. Mir-449 targets c-myc and inhibits NSCLC cell progression. FEBS Lett. 2013;587(9):1359–65.PubMedCrossRef Miao LJ, Huang SF, Sun ZT, Gao ZY, Zhang RX, Liu Y, et al. Mir-449 targets c-myc and inhibits NSCLC cell progression. FEBS Lett. 2013;587(9):1359–65.PubMedCrossRef
40.
Zurück zum Zitat Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y, et al. Mir-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett. 2012;586(20):3761–5.PubMedCrossRef Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y, et al. Mir-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett. 2012;586(20):3761–5.PubMedCrossRef
Metadaten
Titel
MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3
verfasst von
Heying Chu
Xudong Chen
Huaqi Wang
Yuwen Du
Yuanyuan Wang
Wenqiao Zang
Ping Li
Juan Li
Jingxia Chang
Guoqiang Zhao
Guojun Zhang
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1460-1

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.